BioCentury | Mar 5, 2019
Financial News

First close for Seventure's new microbiome fund

Seventure Partners announced the first close of its second microbiome-focused health fund and is targeting a €200 million ($226.9 million) final raise. Seventure's Isabelle de Cremoux said the VC has raised more than half of...
BioCentury | Mar 2, 2019
Product Development

Roche broadens its BD scope

Roche’s proposed acquisition of Spark Therapeutics Inc. is the pharma’s first major deal since James Sabry took over partnering, and could be a glimpse of what’s to come as the pharma broadens its horizons on...
BioCentury | Mar 1, 2019
Product R&D

Mapping microbiome manufacturing

Microbiome companies have been squeezed by the scarcity of contract manufacturers willing to work with tough bacterial strains. While contractors are starting to engage, it could take a big clinical win for them to fully...
BioCentury | Jun 22, 2018
Company News

Roche taps gRED’s Sabry as global head of partnering

A newly created global head of partnering role at Roche (SIX:ROG; OTCQX:RHHBY) is set to combine the pharma’s partnering functions for the first time since it completed its acquisition of Genentech Inc. James Sabry, head...
BioCentury | Jun 8, 2018
Company News

Microbiotica, Genentech in microbiome deal

Genentech Inc. partnered with Microbiotica Ltd. (Cambridge, U.K.) to discover targets and therapeutics for inflammatory bowel disease (IBD) using Microbiotica’s precision metagenomics microbiome platform. Microbiotica will analyze patient samples from the Roche (SIX:ROG; OTCQX:RHHBY) unit’s...
BioCentury | Jun 6, 2018
Company News

Microbiotica, Genentech in microbiome deal

Genentech Inc. partnered with Microbiotica Ltd. (Cambridge, U.K.) to discover targets and therapeutics for inflammatory bowel disease (IBD) using Microbiotica’s precision metagenomics microbiome platform. Microbiotica will analyze patient samples from the Roche (SIX:ROG; OTCQX:RHHBY) unit’s...
BioCentury | Mar 1, 2018
Targets & Mechanisms

Checking out the microbiome

What started out as a potential use in stratifying patients is growing into a new avenue for turning non-responders to responders, as evidence continues to emerge linking the microbiome to immuno-oncology. While the data are...
BioCentury | Feb 15, 2018
Emerging Company Profile

Cultural shift

Microbiotica Ltd. has combined high-precision sequencing, a large reference database and novel culturing approaches to identify and develop commensal bacterial strains, including previously unculturable ones, to treat Clostridium difficile infection and other indications linked to...
BioCentury | May 25, 2017
Finance

Europe’s translational springtime

European science is showing early signs of translational growth, with VCs increasingly shifting their focus to preclinical assets. But investors are concerned the region still doesn’t have the supply of management talent or funding it...
BioCentury | Dec 22, 2016
Financial News

Microbiotica completes venture round

Microbiotica raised £8 million ($10 million) in a venture round from Cambridge Innovation Capital and IP Group. Microbiotica Ltd. , Hinxton, U.K. Alicia Parker Microbiotica Ltd....
Items per page:
1 - 10 of 10
BioCentury | Mar 5, 2019
Financial News

First close for Seventure's new microbiome fund

Seventure Partners announced the first close of its second microbiome-focused health fund and is targeting a €200 million ($226.9 million) final raise. Seventure's Isabelle de Cremoux said the VC has raised more than half of...
BioCentury | Mar 2, 2019
Product Development

Roche broadens its BD scope

Roche’s proposed acquisition of Spark Therapeutics Inc. is the pharma’s first major deal since James Sabry took over partnering, and could be a glimpse of what’s to come as the pharma broadens its horizons on...
BioCentury | Mar 1, 2019
Product R&D

Mapping microbiome manufacturing

Microbiome companies have been squeezed by the scarcity of contract manufacturers willing to work with tough bacterial strains. While contractors are starting to engage, it could take a big clinical win for them to fully...
BioCentury | Jun 22, 2018
Company News

Roche taps gRED’s Sabry as global head of partnering

A newly created global head of partnering role at Roche (SIX:ROG; OTCQX:RHHBY) is set to combine the pharma’s partnering functions for the first time since it completed its acquisition of Genentech Inc. James Sabry, head...
BioCentury | Jun 8, 2018
Company News

Microbiotica, Genentech in microbiome deal

Genentech Inc. partnered with Microbiotica Ltd. (Cambridge, U.K.) to discover targets and therapeutics for inflammatory bowel disease (IBD) using Microbiotica’s precision metagenomics microbiome platform. Microbiotica will analyze patient samples from the Roche (SIX:ROG; OTCQX:RHHBY) unit’s...
BioCentury | Jun 6, 2018
Company News

Microbiotica, Genentech in microbiome deal

Genentech Inc. partnered with Microbiotica Ltd. (Cambridge, U.K.) to discover targets and therapeutics for inflammatory bowel disease (IBD) using Microbiotica’s precision metagenomics microbiome platform. Microbiotica will analyze patient samples from the Roche (SIX:ROG; OTCQX:RHHBY) unit’s...
BioCentury | Mar 1, 2018
Targets & Mechanisms

Checking out the microbiome

What started out as a potential use in stratifying patients is growing into a new avenue for turning non-responders to responders, as evidence continues to emerge linking the microbiome to immuno-oncology. While the data are...
BioCentury | Feb 15, 2018
Emerging Company Profile

Cultural shift

Microbiotica Ltd. has combined high-precision sequencing, a large reference database and novel culturing approaches to identify and develop commensal bacterial strains, including previously unculturable ones, to treat Clostridium difficile infection and other indications linked to...
BioCentury | May 25, 2017
Finance

Europe’s translational springtime

European science is showing early signs of translational growth, with VCs increasingly shifting their focus to preclinical assets. But investors are concerned the region still doesn’t have the supply of management talent or funding it...
BioCentury | Dec 22, 2016
Financial News

Microbiotica completes venture round

Microbiotica raised £8 million ($10 million) in a venture round from Cambridge Innovation Capital and IP Group. Microbiotica Ltd. , Hinxton, U.K. Alicia Parker Microbiotica Ltd....
Items per page:
1 - 10 of 10